Stanwell C, Gescher A, Bradshaw T D, Pettit G R
Pharmaceutical Sciences Institute, Aston University, Birmingham, UK.
Int J Cancer. 1994 Feb 15;56(4):585-92. doi: 10.1002/ijc.2910560420.
Bryostatin I is a natural product currently under clinical evaluation as an antitumor agent. Like the tumor-promoting phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) it activates protein kinase C (PKC). Bryostatin I inhibits the growth of the human-derived A549 lung and MCF-7 adenocarcinoma cell lines, but much more weakly than TPA. The hypotheses were tested that differences between cell lines in their response to bryostatin I are related to cellular PKC isotype content, and that differences between TPA and bryostatin I in their effects on cell growth are associated with differential abilities to modulate specific PKC isoenzymes. PKC isozyme profiles were studied by Western-blot analysis in the cytosol, particulate and nuclear fractions of A549 and MCF-7 cells. PKCs-alpha, -epsilon and -zeta were detected in both cell types with predominant location in the cytosol. Separation of cytosolic PKC isoenzymes in A549 cells by hydroxylapatite column chromatography and determination of PKC activity in fractions yielded a major peak which contained PKC-alpha. Exposure of cells to bryostatin I or TPA for 30 min caused the redistribution of PKCs-alpha and -epsilon from the cytosol to the particulate and nuclear fractions in a concentration-dependent fashion. PKC-epsilon was completely down-regulated by exposure to 10 nM bryostatin I for 18 hr or to TPA for 24 hr. Down-regulation of PKC-alpha was partial at 10 nM and complete at 1 microM of either agent. Bryostatin I inhibited incorporation of [3H]-labelled thymidine into cells only transiently, whereas TPA arrested growth for several days in A549 cells and irreversibly in MCF-7 cells. A549 cells, in which PKC was depleted by exposure to phorbol ester for 9 weeks, were resistant towards bryostatin-induced inhibition of DNA synthesis. The results suggest that the susceptibility of adenocarcinoma cells towards bryostatin-induced growth delay are determined by cellular levels of PKCs-alpha and/or -epsilon. However, differences between bryostatin I and TPA in their abilities to inhibit cell growth do not seem to be intrinsically related to differences in redistribution or down-regulation of specific PKC isoenzymes.
苔藓抑素I是一种正在进行临床评估的天然抗肿瘤药物。与促肿瘤的佛波酯12 - O - 十四酰佛波醇 - 13 - 乙酸酯(TPA)一样,它能激活蛋白激酶C(PKC)。苔藓抑素I抑制人源A549肺癌细胞系和MCF - 7腺癌细胞系的生长,但比TPA的抑制作用弱得多。本研究检验了以下假设:细胞系对苔藓抑素I反应的差异与细胞PKC同工型含量有关,以及TPA和苔藓抑素I对细胞生长影响的差异与调节特定PKC同工酶的不同能力相关。通过蛋白质免疫印迹分析研究了A549和MCF - 7细胞的胞质、微粒体和细胞核部分中的PKC同工酶谱。在两种细胞类型中均检测到PKC -α、-ε和 -ζ,主要位于胞质中。通过羟基磷灰石柱色谱法分离A549细胞中的胞质PKC同工酶,并测定各组分中的PKC活性,得到一个主要峰,其中含有PKC -α。将细胞暴露于苔藓抑素I或TPA 30分钟会导致PKC -α和 -ε以浓度依赖的方式从胞质重新分布到微粒体和细胞核部分。暴露于10 nM苔藓抑素I 18小时或TPA 24小时可使PKC -ε完全下调。在10 nM时PKC -α的下调是部分的,而在1 μM的任何一种药物作用下则完全下调。苔藓抑素I仅短暂抑制[³H]标记的胸苷掺入细胞,而TPA在A549细胞中使生长停滞数天,在MCF - 7细胞中则不可逆地抑制生长。通过暴露于佛波酯9周使PKC耗竭的A549细胞对苔藓抑素诱导的DNA合成抑制具有抗性。结果表明,腺癌细胞对苔藓抑素诱导的生长延迟的敏感性由细胞中PKC -α和/或 -ε的水平决定。然而,苔藓抑素I和TPA在抑制细胞生长能力上的差异似乎与特定PKC同工酶的重新分布或下调差异并无内在关联。